The Intro-to-Maintenance Price Jump
By month 4 of a GLP-1 program, two things have typically happened: your dose has escalated beyond the starter level, and any introductory pricing has expired. These two factors combine to produce what we call the "month-4 reality" — the first billing cycle where you see your true ongoing cost.
For flat-rate providers, month 4 looks identical to month 1. For tiered or intro-priced providers, it can be a rude awakening.
Month-4 Pricing at Major Providers
| Provider | Month 1 | Month 4 | Increase | Why |
|---|---|---|---|---|
| GobyMeds | $99 | $99 | $0 | Flat-rate, no intro pricing |
| Trimi | $99 | $99 | $0 | Flat-rate, no intro pricing |
| Gala | $179 | $179 | $0 | Flat-rate, no intro pricing |
| Telos Rx (12-mo) | $49 | $49 | $0 | Commitment-flat |
| Oak Longevity | $130 | $130 | $0 | Flat-rate |
| Sunlight | $159 | $179 | +$20 | Intro → standard rate |
| Embody | $149 | ~$249–$299 | +$100–$150 | Intro expires + dose tier |
| Yucca Health | $149 | ~$249–$289 | +$100–$140 | Dose-tier increase |
| NovoCare Wegovy | $199 | $349 | +$150 | Intro rate (2 fills only) |
The Flat-Rate Advantage at Month 4
Month 1: $99. Month 4: $99. Month 12: $99. Month 36: $99. No intro gimmick, no dose-tier escalation. The simplicity is the feature.
$179 from day one through year three and beyond. The price is the price.
On the 12-month plan, $49/month from start to finish. The commitment is the trade-off for the consistency.
Understanding Why Intro Rates Exist
Intro pricing is not inherently dishonest. Providers use it for legitimate business reasons:
- Lower barrier to entry. A $149 first month gets patients to start who might balk at $299. Once they experience results, retention is high.
- Lower-dose costs less. At 0.25mg, the actual medication cost is lower. Some providers pass through the cost difference rather than averaging it across all doses.
- Competitive positioning. In a market where comparison sites sort by "starting price," the lowest first-month rate wins eyeballs regardless of the 12-month total.
The issue is not that intro pricing exists — it is how prominently the maintenance rate is disclosed alongside the intro rate. Providers that bury the month-4 price in FAQ pages or terms of service are exploiting the intro rate as a bait-and-switch, even if it is technically disclosed.
💡 Before enrolling at any intro-priced provider, ask one question: 'What will my monthly cost be at 1.7mg semaglutide, after any introductory period has ended, including all fees?' Write down the answer. Compare it to flat-rate alternatives. Then decide.
The Annual Impact of Month-4 Pricing
| Provider | Months 1–3 Total | Months 4–12 Total | Full Year |
|---|---|---|---|
| GobyMeds ($99 flat) | $297 | $891 | $1,188 |
| Gala ($179 flat) | $537 | $1,611 | $2,148 |
| Intro @ $149 → $299 maint. | $447 | $2,691 | $3,138 |
| NovoCare ($199 → $349) | $597* | $3,141 | $3,738* |
*NovoCare intro applies to first 2 fills only; month 3 already at $349.
The year-one gap between a $99 flat provider and a $149-intro/$299-maintenance provider exceeds $1,900. That is the true cost of the intro rate — not $149, but the $299 you pay for the remaining 9 months.
How to Protect Yourself
- Always calculate the 12-month total. Multiply the maintenance rate by 9, add the intro months. Compare that number — not the first-month price.
- Ask for the maintenance rate in writing. Verbal quotes are worthless. Get the month-4+ rate documented in your enrollment terms or via email.
- Set a month-3 reminder. Review your bill at month 3 before the intro period ends. If the jump is unacceptable, you have time to switch.
- Compare against flat-rate alternatives. A $99/month flat provider costs less annually than a $149-intro provider in nearly every scenario.
The Bottom Line
Month 4 is when GLP-1 pricing gets real. The intro rate is the sizzle; the maintenance rate is the steak. Flat-rate providers eliminate the surprise entirely — your month-4 bill is your month-1 bill. If you are currently on an intro-priced program approaching month 4, check our comparison board to see whether switching to a flat-rate provider saves you money over the next 12 months.
⚠️ Compounded GLP-1 medications are not FDA-approved. Never stop medication abruptly without consulting your prescriber. If switching providers, plan the transition with your clinician.